Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are proteins that interact in the circulatory system and pericellular region to regulate fibrinolysis, cell adhesion, and migration. The interactions between the two proteins have been attributed primarily to binding of the somatomedin B (SMB) domain, which comprises the N-terminal 44 residues of vitronectin, to the flexible joint region of PAI-1, including residues Arg-103, Met-112, and Gln-125 of PAI-1. A strategy for deletion mutagenesis that removes the SMB domain demonstrates that this mutant form of vitronectin retains PAI-1 binding (Schar, C. R., Blouse, G. E., Minor, K. M., and Peterson, C. B. (2008) J. Biol. Chem. 283, 10297-10309). In the current study, the complementary binding site on PAI-1 was mapped by testing for the ability of a battery of PAI-1 mutants to bind to the engineered vitronectin lacking the SMB domain. This approach identified a second, separate site for interaction between vitronectin and PAI-1. The binding of PAI-1 to this site was defined by a set of mutations in PAI-1 distinct from the mutations that disrupt binding to the SMB domain. Using the mutations in PAI-1 to map the second site suggested interactions between ␣-helices D and E in PAI-1 and a site in vitronectin outside of the SMB domain. The affinity of this second interaction exhibited a K D value ϳ100-fold higher than that of the PAI-1-somatomedin B interaction. In contrast to the PAI-1-somatomedin B binding, the second interaction had almost the same affinity for active and latent PAI-1. We hypothesize that, together, the two sites form an extended binding area that may promote assembly of higher order vitronectin-PAI-1 complexes.Vitronectin is a circulatory protein that interacts with several other plasma components that regulate coagulation and fibrinolysis, cell lysis via the complement cascade, and cell binding and migration in an integrin-dependent and urokinase-type plasminogen activator receptor-dependent fashion (1, 2). An interaction with vitronectin that has been widely studied occurs with the serine protease inhibitor (or serpin), PAI-1, 2 the primary inhibitor of urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA). Most circulating PAI-1 is found in a complex with vitronectin (3). The formation of the complex between vitronectin and PAI-1 is presumed to be physiologically significant in several respects. Binding of vitronectin to PAI-1 stabilizes the active conformation of the serpin, increasing the half-life for its conversion to the inactive, so-called latent state, and maintains its protease inhibitory properties for a prolonged period (4, 5). PAI-1 binds to the N-terminal ϳ50-amino acid somatomedin B (SMB) domain of vitronectin. The binding of PAI-1 competes with the binding of the urokinase-type plasminogen activator receptor to this domain and with the binding of integrins to the adjacent RGD sequence (for a review, see Ref. 6). Moreover, PAI-1 has been reported to induce oligomerization of vitronectin (7-10).Th...